Skip to content
Screener

Enliven Therapeutics ELVN Total Liabilities & Equity

Total Liabilities & Equity at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$87.63B-7.4%
Pfizer logo
PfizerPFE
$207.62B-0.2%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$646.64M+113%
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
$915.53M+0.9%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$472.67M-26.2%
CTO
Citius Oncology, Inc.CTOR
$100.7M+10.1%

Other financials

Income statement

See full
Operating income-$27.8M+12.2%
Net income-$23.6M+17.2%
EPS (diluted)-$0.38+33.3%

Balance sheet

See full
Cash & equivalents$132.2M+30.0%
Total debt$302.0K-56.9%
Total equity$453.4M+57.3%
Total assets$464.9M+53.6%

Cash flow

See full
Operating cash flow-$19.3M+20.0%
CapEx--100%
Free cash flow-$19.3M+20.1%

Valuation

See full
Market cap$4.42B+297%
Enterprise value$4.28B+332%

Returns & leverage

See full
Return on equity-26.6%-3.5pp
Debt / equity0.0×
Current ratio40.3×+19.3×

Where this comes from

Reported directly by Enliven Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: Enliven Therapeutics’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:17 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-211982
Line itemAs of / March 31, 2026As of / December 31, 2025
Stockholders' equity:
Preferred stock, par value $0.001; authorized shares - 10,000,000;issued and outstanding shares - none
Common stock, par value $0.001; authorized shares - 100,000,000;issued and outstanding shares - 60,889,655 and 59,440,045 atMarch 31, 2026 and December 31, 2025, respectively6159
Additional paid-in capital824,479806,373
Accumulated other comprehensive (loss) income(382)334
Accumulated deficit(370,793)(347,166)
Total stockholders’ equity453,365459,600
Total liabilities and stockholders' equity$464,852$476,168

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Enliven Therapeutics's total liabilities & equity?
Enliven Therapeutics (ELVN) reported total liabilities & equity of $464.85M in Q1 2026.
How has Enliven Therapeutics's total liabilities & equity changed year-over-year?
Enliven Therapeutics's total liabilities & equity increased by 53.6% year-over-year, from $302.57M to $464.85M.
What is the long-term trend for Enliven Therapeutics's total liabilities & equity?
Over 5 years (2020 to 2025), Enliven Therapeutics's total liabilities & equity has grown at a 39.3% compound annual growth rate (CAGR), from $90.84M to $476.17M.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about Enliven Therapeutics's total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude